An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness.

Property Value
dbo:abstract
  • Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness. Lisocabtagene maraleucel, a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, is the third gene therapy approved by the U.S. Food and Drug Administration (FDA) for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Lisocabtagene maraleucel was approved for medical use in the United States in February 2021. (en)
  • Лисокабтаген маралеусел — лекарственный препарат для генной терапии B-крупноклеточной лимфомы. Одобрен для применения: США (2021) (ru)
dbo:alternativeName
  • Breyanzi (en)
dbo:chEMBL
  • 4297236
dbo:class
dbo:drugbank
  • DB16582
dbo:fdaUniiCode
  • 7K2YOJ14X0
dbo:kegg
  • D11990
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 57641853 (xsd:integer)
dbo:wikiPageLength
  • 15113 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1112989893 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:chembl
  • 4297236 (xsd:integer)
dbp:class
dbp:dailymedid
  • Lisocabtagene_maraleucel (en)
dbp:drugbank
  • DB16582 (en)
dbp:gtTargetGene
dbp:kegg
  • D11990 (en)
dbp:legalCa
  • Rx-only (en)
dbp:legalCaComment
  • /Schedule D (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:routesOfAdministration
dbp:synonyms
  • JCAR017, LM (en)
dbp:tradename
  • Breyanzi (en)
dbp:unii
  • 7 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Лисокабтаген маралеусел — лекарственный препарат для генной терапии B-крупноклеточной лимфомы. Одобрен для применения: США (2021) (ru)
  • Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness. (en)
rdfs:label
  • Lisocabtagene maraleucel (en)
  • Lisocabtagene maraleucel (ru)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License